Top U.S. Defense Stocks to Watch According to Jefferies Analysis
Lilly Endowment Inc. sold shares of Eli Lilly & Co (NYSE:LLY) on October 10, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The sales amounted to a total of $3.16 million.
The transactions involved the sale of 3,658 shares of common stock in two separate transactions. The prices obtained for the shares ranged from $862.34 to $863.369. Specifically, 468 shares were sold at a weighted average price of $862.34, with prices ranging from $862.00 to $862.74. An additional 3,190 shares were sold at a weighted average price of $863.369, with prices ranging from $863.00 to $863.995. The stock, which has maintained dividend payments for 55 consecutive years, currently yields 0.73%.
Following these transactions, Lilly Endowment Inc. directly owns 94,533,320 shares of Eli Lilly & Co.
Diane M. Stenson, Vice President & Treasurer, signed the report on behalf of Lilly Endowment Inc.
In other recent news, Eli Lilly has been upgraded by Erste Group from Hold to Buy following the company’s robust first-half results. The pharmaceutical giant has also raised its full-year 2025 guidance for both revenue and earnings per share. Guggenheim has increased its price target for Eli Lilly to $948, maintaining a Buy rating, citing strong expectations for the third-quarter sales of its diabetes drug, Mounjaro. Additionally, TD Cowen has reiterated its Buy rating with a price target of $960, highlighting Eli Lilly’s growth prospects and consistent innovation.
Eli Lilly is set to present significant data at the European Society for Medical Oncology Annual Meeting, focusing on its breast cancer drug, Verzenio. The presentation will cover the seven-year analysis of the drug’s efficacy in high-risk early breast cancer. Furthermore, the company announced that its ulcerative colitis treatment, Omvoh, has shown sustained efficacy over four years, with a high percentage of patients maintaining clinical remission. These developments reflect Eli Lilly’s ongoing commitment to advancing its pharmaceutical offerings.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.